To Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected Into the Mid-Face

A Multicenter, Randomized, Rater-Blinded, No-Treatment Control Design Clinical Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected Into the Mid-Face

To Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected Into the Mid-Face

Inclusion Criteria:

• Male or female adults 18 to 65 years of age (inclusive)
• 3 (moderate) or 4 (severe) on MFVDA-SRS
• sign the written informed consent form

Exclusion Criteria:

• have streptococcal disease or bleeding disorder
• have an active or infective skin disease, scars, or tumor on mid-face
• have congenital defect, trauma, abnormalities in adipose tissue related to immune-mediated diseases
• have undergone facial plastic surgery, tissue grafting, or tissue augmentation with silicone, fat, or other permanent, or semi-permanent procedures/treatment
• have undergone temporary facial dermal filler within 12 months, porcine-based collagen fillers within 24 months, or neuromodulator injections, mesotherapy, or resurfacing within 6 months
• have a medical history of hypertrophic cicatrix or keloid
• have radiation therapy experience on mid-face
• have a history of anaphylaxis, multiple severe allergies, atopy, or allergy to lidocaine, hyaluronic acid products, or Streptococcal protein